Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00238173CT.gov Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Marrow Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | Fred Hutchinson Cancer Center | P2 | B · 60 |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Piperacillin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Tazobactam | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Vancomycin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | B |
| Treosulfan | Fred Hutchinson Cancer Center | P2 | B |
| Atorvastatin | Fred Hutchinson Cancer Center | P2 | B |
| Ruxolitinib | Constellation Pharmaceuticals | P1/2 | CCC |
+18 more in the Bone Marrow Disorder cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FludarabineFred Hutchinson Cancer CenterBB
- PiperacillinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- TazobactamEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- VancomycinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- Cyclosporin AFred Hutchinson Cancer CenterB
Citation
Floatz Terminal. Nivestim in Bone Marrow Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-bone-marrow-disorder-61286
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →